Is ARDX or IMRX more profitable?

Immuneering has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Immuneering's return on equity of -31.93% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -13.58% -38.11% -11.85% Immuneering N/A -31.93% -29.92%

Does the media favor ARDX or IMRX?

In the previous week, Immuneering had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Immuneering and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Immuneering's score of 0.07 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to IMRX or IMCR?

In the previous week, Immuneering had 2 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Immuneering and 3 mentions for Immunocore. Immunocore's average media sentiment score of 0.63 beat Immuneering's score of 0.07 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMRX or PURR more profitable?

Immuneering's return on equity of -31.93% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Hyperliquid Strategies N/A -56.04% -52.22%

Does the media refer more to IMRX or PURR?

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Hyperliquid Strategies and 5 mentions for Immuneering. Hyperliquid Strategies' average media sentiment score of 0.83 beat Immuneering's score of 0.07 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Hyperliquid Strategies 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KALV or IMRX more profitable?

Immuneering's return on equity of -31.93% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets KalVista Pharmaceuticals N/A -341.44% -111.94% Immuneering N/A -31.93% -29.92%

Does the media prefer KALV or IMRX?

In the previous week, Immuneering had 1 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 5 mentions for Immuneering and 4 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.62 beat Immuneering's score of 0.07 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, MLTX or IMRX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is MLTX or IMRX more profitable?

Immuneering's return on equity of -31.93% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -85.15% -60.52% Immuneering N/A -31.93% -29.92%

Does the media favor MLTX or IMRX?

In the previous week, MoonLake Immunotherapeutics and MoonLake Immunotherapeutics both had 5 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Immuneering's score of 0.07 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Immuneering (IMRX) Competitors

$4.55 +0.27 (+6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$4.53 -0.02 (-0.46%)

As of 06:52 PM Eastern

Compare

IMRX vs. ARDX, IMCR, PURR, KALV, and MLTX

Should you buy Immuneering stock or one of its competitors? MarketBeat compares Immuneering with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuneering include Ardelyx (ARDX), Immunocore (IMCR), Hyperliquid Strategies (PURR), KalVista Pharmaceuticals (KALV), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

How does Immuneering compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Immuneering has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Immuneering's return on equity of -31.93% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Immuneering	N/A	-31.93%	-29.92%

Ardelyx currently has a consensus price target of $15.70, suggesting a potential upside of 189.67%. Immuneering has a consensus price target of $16.50, suggesting a potential upside of 262.64%. Given Immuneering's higher probable upside, analysts plainly believe Immuneering is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Immuneering had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Immuneering and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Immuneering's score of 0.07 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Immuneering has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.29	-$61.60M	-$0.23	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Ardelyx has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Summary

Immuneering beats Ardelyx on 8 of the 15 factors compared between the two stocks.

How does Immuneering compare to Immunocore?

Immuneering (NASDAQ:IMRX) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immuneering has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Immunocore	-6.68%	-7.07%	-2.55%

Immuneering presently has a consensus price target of $16.50, indicating a potential upside of 262.64%. Immunocore has a consensus price target of $56.71, indicating a potential upside of 97.96%. Given Immuneering's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immuneering is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Immuneering had 2 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Immuneering and 3 mentions for Immunocore. Immunocore's average media sentiment score of 0.63 beat Immuneering's score of 0.07 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Immuneering. Immunocore is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Immunocore	$400.02M	3.63	-$35.51M	-$0.55	N/A

Summary

Immunocore beats Immuneering on 8 of the 15 factors compared between the two stocks.

How does Immuneering compare to Hyperliquid Strategies?

Immuneering (NASDAQ:IMRX) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

67.7% of Immuneering shares are held by institutional investors. Comparatively, 9.4% of Hyperliquid Strategies shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Hyperliquid Strategies has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Hyperliquid Strategies	$1M	1,497.93	-$16.01M	-$7.37	N/A

Immuneering currently has a consensus price target of $16.50, suggesting a potential upside of 262.64%. Hyperliquid Strategies has a consensus price target of $9.25, suggesting a potential downside of 10.80%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts clearly believe Immuneering is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Immuneering's return on equity of -31.93% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Hyperliquid Strategies and 5 mentions for Immuneering. Hyperliquid Strategies' average media sentiment score of 0.83 beat Immuneering's score of 0.07 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Hyperliquid Strategies	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Summary

Immuneering beats Hyperliquid Strategies on 9 of the 15 factors compared between the two stocks.

How does Immuneering compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Immuneering had 1 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 5 mentions for Immuneering and 4 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.62 beat Immuneering's score of 0.07 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

67.7% of Immuneering shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Immuneering has lower revenue, but higher earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$49.08M	29.23	-$109.52M	-$3.46	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

KalVista Pharmaceuticals has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

KalVista Pharmaceuticals presently has a consensus target price of $30.60, indicating a potential upside of 13.56%. Immuneering has a consensus target price of $16.50, indicating a potential upside of 262.64%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering's return on equity of -31.93% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Immuneering	N/A	-31.93%	-29.92%

Summary

Immuneering beats KalVista Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Immuneering compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

MoonLake Immunotherapeutics currently has a consensus price target of $23.85, indicating a potential upside of 30.52%. Immuneering has a consensus price target of $16.50, indicating a potential upside of 262.64%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering's return on equity of -31.93% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Immuneering	N/A	-31.93%	-29.92%

In the previous week, MoonLake Immunotherapeutics and MoonLake Immunotherapeutics both had 5 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Immuneering's score of 0.07 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

Summary

Immuneering beats MoonLake Immunotherapeutics on 9 of the 13 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$294.37M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-3.89	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	1.35	6.63	9.84	6.72
Net Income	-$56.03M	$24.20M	$3.57B	$337.19M
7 Day Performance	-14.79%	-3.24%	-1.16%	0.48%
1 Month Performance	-15.27%	0.53%	3.85%	5.07%
1 Year Performance	132.14%	47.24%	27.40%	34.25%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.2335 of 5 stars	$4.55 +6.3%	$16.50 +262.6%	+128.9%	$294.37M	N/A	N/A	60	Analyst Forecast
ARDX Ardelyx	2.8941 of 5 stars	$5.51 -3.9%	$15.70 +185.2%	+43.4%	$1.49B	$427.68M	N/A	90
IMCR Immunocore	2.7641 of 5 stars	$28.75 -1.3%	$56.71 +97.2%	-23.5%	$1.48B	$412.81M	N/A	320	High Trading Volume
PURR Hyperliquid Strategies	1.472 of 5 stars	$11.16 +2.7%	$9.25 -17.1%	N/A	$1.44B	$1M	N/A	N/A	Gap Up High Trading Volume
KALV KalVista Pharmaceuticals	2.5233 of 5 stars	$26.95 +0.0%	$30.60 +13.6%	+108.5%	$1.43B	$1.43M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. ARDX, IMCR, PURR, KALV, and MLTX

How does Immuneering compare to Ardelyx?

Summary

How does Immuneering compare to Immunocore?

Summary

How does Immuneering compare to Hyperliquid Strategies?

Summary

How does Immuneering compare to KalVista Pharmaceuticals?

Summary

How does Immuneering compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. ARDX, IMCR, PURR, KALV, and MLTX

How does Immuneering compare to Ardelyx?

Is ARDX or IMRX more profitable?

Do analysts rate ARDX or IMRX?

Does the media favor ARDX or IMRX?

Do insiders and institutionals hold more shares of ARDX or IMRX?

Which has better valuation and earnings, ARDX or IMRX?

Which has more volatility and risk, ARDX or IMRX?

Summary

How does Immuneering compare to Immunocore?

Do insiders & institutionals have more ownership in IMRX or IMCR?

Is IMRX or IMCR more profitable?

Do analysts prefer IMRX or IMCR?

Does the media refer more to IMRX or IMCR?

Which has more volatility and risk, IMRX or IMCR?

Which has preferable valuation & earnings, IMRX or IMCR?

Summary

How does Immuneering compare to Hyperliquid Strategies?

Do insiders and institutionals hold more shares of IMRX or PURR?

Which has better earnings & valuation, IMRX or PURR?

Do analysts prefer IMRX or PURR?

Is IMRX or PURR more profitable?

Does the media refer more to IMRX or PURR?

Which has more volatility & risk, IMRX or PURR?

Summary

How does Immuneering compare to KalVista Pharmaceuticals?

Does the media prefer KALV or IMRX?

Do insiders and institutionals hold more shares of KALV or IMRX?

Which has higher earnings and valuation, KALV or IMRX?

Which has more risk & volatility, KALV or IMRX?

Do analysts rate KALV or IMRX?

Is KALV or IMRX more profitable?

Summary

How does Immuneering compare to MoonLake Immunotherapeutics?

Do analysts prefer MLTX or IMRX?

Is MLTX or IMRX more profitable?

Does the media favor MLTX or IMRX?

Which has preferable valuation & earnings, MLTX or IMRX?

Do insiders and institutionals hold more shares of MLTX or IMRX?

Which has more volatility & risk, MLTX or IMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools